Ashurst advised Perspix Biotech GmbH on the deal. Perspix Biotech GmbH, a biopharma company committed to create efficient next-generation biotherapeutics, entered in the market. Frankfurt-based Perspix...
Perspix Biotech GmbH’s Market Entry in AI-driven Drug Development
BioMedion GmbH’s Strategic Investment of Main Capital Partners
Ashurst advised BioMedion GmbH on the deal. Berlin-based BioMedion was founded in 2000 and is active in the field of regulated industries. The company provides state-of-the-art...
hGears’ €173 Million Initial Public Offering
CMS advised minority shareholders HPH Beteiligung and M-H Herzog Beteiligung on all legal aspects. Hogan Lovells advised Hauck & Aufhäuser Privatbankiers AG and ABN AMRO Bank...
NFON AG’s EUR 26.3 Million Capital Increase
CMS advised NFON AG on all legal aspects of structuring and implementing the capital increase. Ashurst advised Joh. Berenberg, Gossler & Co. KG. Munich-based NFON AG...
Silverfleet Capital’s Acquisition of ec4u and BULPROS
Latham & Watkins LLP and Shearman & Sterling advised Silverfleet Capital on the deal. Ashurst advised Ares. Silverfleet Capital executed the acquisition of ec4u and BULPROS....
Silverfleet Capital’s Acquisition of ec4u and BULPROS
Latham & Watkins LLP advised Silverfleet Capital on the deal. Ashurst advised Ares. Silverfleet Capital executed the acquisition of ec4u and BULPROS. The company founders and...